Novogen is a rapidly expanding international biotechnology company based in Australia and the USA.


Novogen has three key aims:



  1. To maintain its position as the world leader in the area of isoflavonoid drug technology;

  2. To convert the Novogen technology platform into products that will successfully treat and prevent the major degenerative diseases of humans;

  3. To establish a business model and investment opportunity that will return increasing value to shareholders.


 








Marshall Edwards oppoints oncologist Christine White to its Board
10 August 2010
Novogen Limited’s subsidiary, Marshall Edwards, Inc., (NASDAQ: ...More



Novogen receives Nasdaq notice
23 July 2010
Novogen Limited (ASX: NRT NASDAQ:NVGN) is listed on the ...More



Novogen restructures Australian management team and Marshall Edwards appoints CFO
18 June 2010
Novogen Limited’s subsidiary, Marshall Edwards, Inc., (NASDAQ: ...More






Chairman's address to the 2009 Annual General Meeting
Friday, 30 October 2009
Chairman’s address to the Annual General Meeting of Novogen Limited
I am pleased to present to our valued
...More
 


About Novogen | Knowledge Base | Consumer Health | Pharmaceuticals | News | Investor Relations | Contact | Site Map
Copyright © 2010 Novogen The world leader in isoflavone research - with products including Promensil and Trinovin | Web Design by Newgency